By John Carroll
Created Sep 3 2009 – 9:20am
Racing to produce a huge quantity ofÃ‚Â vaccine toÃ‚Â fight an expectedÃ‚Â tsunami ofÃ‚Â swine flu casesÃ‚Â this fall, Novartis says that a single low dose of itsÃ‚Â Celtura jab produced an immune response sufficient to protect theÃ‚Â volunteers enrolled in a small trial.
The cell culture-based vaccine–which includes an adjuvant to boost its efficacy–was tested in a trial involving 100 people, says the giant pharma manufacturer.Ã‚Â Health officials in the U.S. are likely to recommend a traditional two-shot approach to swine flu. With no built-in immunity to the new flu, it typically takes a booster shot to fully protect people from a virus like this. But with plans to inoculate hundreds of millions of people around the globe in a short period, a single-shot approach could provide wider protection that would blunt the size and speed of the second wave.
“The pilot trial results are encouraging,” said Andrin Oswald, chief executive officer of Novartis Vaccines and Diagnostics. “While two doses seem to provide better protection, one dose of our adjuvanted Celtura vaccine may be sufficient to protect adults against the swine flu. This is important information for public health authorities who prepare for vaccination in the coming months with limited vaccine supply.” Novartis is now testing Celtura in trials involving 6,000 subjects.
VacTRUTH Author’s Note:
1. One can only wonder how Novartis came to the conclusion that their vaccine was a success. Safety trials are still occurring here.
2. It appears neurologists are not apart of testing the long-term safety of vaccines. Volunteers are going to be monitored for 13 months here.
3. 1976 Swine Flu vaccine caused Gullian Barre syndrome. Watch it here.
4. All vaccines cause disease and death. Read about it here.
5. Want to stop vaccines from becoming mandatory? Learn what to do here and take action.